Orogen Royalties Inc
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2020-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.organon.com
- Introduction
Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.
A Study of Losartan Compared to Losartan/HCTZ in Pediatric Patients With Hypertension (0954A-327)
Phase 3
Terminated
- Conditions
- Hypertension
- Interventions
- Drug: hydrochlorothiazide (+) losartan potassiumDrug: losartan potassiumDrug: Placebo for Losartan/HCTZDrug: Placebo for Losartan
- First Posted Date
- 2007-03-15
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 40
- Registration Number
- NCT00447603
MK0476 Study in Adult Patients With Allergic Rhinitis (0476-378)
Phase 2
Completed
- Conditions
- Rhinitis Allergic
- First Posted Date
- 2007-03-12
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 945
- Registration Number
- NCT00446186
Montelukast Post-Marketing Comparative Study With Ketotifen (0476-379)
Phase 4
Completed
- Conditions
- Asthma
- First Posted Date
- 2007-03-12
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 188
- Registration Number
- NCT00446056
SINGULAIR (R) as Complementary Therapy to Fixed Association Regimen (0476-363)
Phase 3
Completed
- Conditions
- Asthma
- First Posted Date
- 2007-03-08
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 198
- Registration Number
- NCT00445107
Vytorin (10/20 Or 10/40) Compared to Atorvastatin (10 mg or 20 mg) in Patients With Coronary Artery Disease (0653A-126)(COMPLETED)
- First Posted Date
- 2007-03-05
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 229
- Registration Number
- NCT00442897
Montelukast in Mild Asthmatic Children With Allergic Rhinitis (0476-367)
Phase 4
Completed
- Conditions
- Allergic RhinitisAsthma
- Interventions
- Drug: montelukast sodiumDrug: inhaled corticosteroid
- First Posted Date
- 2007-03-02
- Last Posted Date
- 2024-05-13
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 191
- Registration Number
- NCT00442559
A Comparison of Mometasone Furoate DPI Versus Budesonide DPI in Budesonide DPI in Asthmatics (Study P04880)
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2007-03-01
- Last Posted Date
- 2024-05-20
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 180
- Registration Number
- NCT00442117
Efficacy and Tolerability of Maintenance Treatment With Asmanex Twisthaler Versus Placebo in Mild/Moderate Persistent Asthmatics (Study P04654)(TERMINATED)
Phase 4
Terminated
- Conditions
- Asthma
- Interventions
- Other: Placebo for Asmanex twisthalerDrug: Asmanex twisthaler
- First Posted Date
- 2007-03-01
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 26
- Registration Number
- NCT00442351
Study of MK-0476 in Adult Patients With Acute Asthma (0476-334)
- First Posted Date
- 2007-03-01
- Last Posted Date
- 2022-02-02
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 91
- Registration Number
- NCT00442338
Trial to Compare the Effects of Tibolone (Livial®) and Continuous Combined Low-Dose Estradiol/Noresterone (Activelle®)
- First Posted Date
- 2007-02-05
- Last Posted Date
- 2022-02-03
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 570
- Registration Number
- NCT00431093
© Copyright 2025. All Rights Reserved by MedPath